$5.61
−5.08%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$5.80
From 52W high−53.21%
Volume9363.00
Market cap$531.96M
P/E (TTM)—
P/S (TTM)3.3x
Div yield—
Key dataOct 16, 2026
Open
$5.80
From 52W high
−53.21%
Volume
9363.00
Market cap
$531.96M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.0x
P/E (TTM)
—
RSI (14)
39.5
MomentumView details →
1D Return
−5.08%
YTD Return
−36.73%
SummaryUpdated Jun 1, 2026
Valneva SE (NASDAQ:VALN) is a French specialty vaccine company founded in 1998 and headquartered in Saint-Herblain, France. The company went public on NASDAQ in May 2021, having previously traded on European exchanges. Valneva focuses on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs, particularly targeting travel-related and emerging infectious diseases. The company has evolved from a pure research and development organization into a commercial-stage biotechnology company with marketed products and a robust pipeline of vaccine candidates in various stages of clinical development.
Similar companies
Latest newsMore news →
French pharmaceutical stocks Genfit, Nanobiotix and Valneva SE fell between 4.8% and 6.2%.9d agoThe United Kingdom’s Medicines and Healthcare products Regulatory Agency revoked Valneva’s marketing authorization for IXCHIQ following a benefit-risk assessment by the Commission on Human Medicines.9d agoThe European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.64d ago